Ardelyx Is Maintained at Buy by Citigroup
Ardelyx's Strong Sales and Strategic Positioning Reinforce Buy Rating Amid Reimbursement Uncertainties
A Quick Look at Today's Ratings for Ardelyx(ARDX.US), With a Forecast Between $7 to $13.5
Ardelyx Analyst Ratings
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Piper Sandler Remains a Hold on Ardelyx (ARDX)
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Ardelyx (ARDX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Ardelyx Analyst Ratings
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Raises Target Price to $11
Ardelyx: Strong Sales Growth and Strategic Expansion Drive Buy Rating
Ardelyx Analyst Ratings
A Quick Look at Today's Ratings for Ardelyx(ARDX.US), With a Forecast Between $7 to $12
Ardelyx's Robust Drug Performance and Growth Potential Warrants a Buy Rating
Piper Sandler Gives a Hold Rating to Ardelyx (ARDX)
Piper Sandler Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $7
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
No Data
No Data